Self‐initiated use of topical cannabidiol oil for epidermolysis bullosa

Chelliah, Malcolm P.; Zinn, Zachary; Khuu, Phuong; Teng, Joyce

doi:10.1111/pde.13545

Cited by 105 publications

(81 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A particularly interesting, although anecdotal, result has recently been published by Chelliah et al, who described the benefits that CBD provided as anti-inflammatory agent in three patients affected by epidermiolysis bullosa. Paediatric patients benefited from the use of topical CBD (applied as an oil, cream and spray by their parents) leading to a reduction in pain and blistering as well as rapid wound healing [ 100 ]. There were no adverse effects reported, either by the patients or their families, of this topical use of CBD.…”

Section: Current Drug Dosage Forms and Novel Delivery Systemsmentioning

confidence: 99%

Cannabinoid Delivery Systems for Pain and Inflammation Treatment

Bruni¹,

et al. 2018

View full text Add to dashboard Cite

There is a growing body of evidence to suggest that cannabinoids are beneficial for a range of clinical conditions, including pain, inflammation, epilepsy, sleep disorders, the symptoms of multiple sclerosis, anorexia, schizophrenia and other conditions. The transformation of cannabinoids from herbal preparations into highly regulated prescription drugs is therefore progressing rapidly. The development of such drugs requires well-controlled clinical trials to be carried out in order to objectively establish therapeutic efficacy, dose ranges and safety. The low oral bioavailability of cannabinoids has led to feasible methods of administration, such as the transdermal route, intranasal administration and transmucosal adsorption, being proposed. The highly lipophilic nature of cannabinoids means that they are seen as suitable candidates for advanced nanosized drug delivery systems, which can be applied via a range of routes. Nanotechnology-based drug delivery strategies have flourished in several therapeutic fields in recent years and numerous drugs have reached the market. This review explores the most recent developments, from preclinical to advanced clinical trials, in the cannabinoid delivery field, and focuses particularly on pain and inflammation treatment. Likely future directions are also considered and reported.

show abstract

Section: Current Drug Dosage Forms and Novel Delivery Systemsmentioning

confidence: 99%

Cannabinoid Delivery Systems for Pain and Inflammation Treatment

Bruni¹,

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Regarding the clinical efficiency of cannabinoids in human skin fibrotic diseases, only scarce evidence is available. A short literature report including three patients exhibiting epidermolysis bullosa described faster wound healing following the selfadministration of cannabidiol (CBD) 34 . Recently, a small clinical study described a beneficial effect of topical cannabidiol in acne scars 35 .…”

mentioning

confidence: 99%

A new role for anandamide: defective link between the systemic and skin endocannabinoid systems in hypertrophic human wound healing

Correia‐Sá

Carvalho

Serrão

et al. 2020

Sci Rep

View full text Add to dashboard Cite

The use of cannabinoids to treat fibrotic skin diseases is an emergent issue. Therefore, we aimed to evaluate systemic and skin endocannabinoid responses in the wound-healing process in humans. A prospective study was performed in 50 patients who underwent body-contouring surgery. Anandamide (N-arachidonoylethanolamine, AEA), 2-arachidonoylglycerol (2-AG), palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) were quantified using LC-MS/MS. Ten (20%) patients developed hypertrophic (HT) scars. No significant changes were observed between the normal (N) scar and HT scar groups in terms of plasma and skin endocannabinoids. Nevertheless, a positive correlation between plasma and skin AEA concentrations was found in the N group (r = 0.38, p = 0.015), which was absent in the HT group. Moreover, the AEA concentration was significantly lower in HT scar tissue than in normal scar tissue (0.77 ± 0.12 ng/g vs 1.15 ± 0.15 ng/g, p < 0.001). Interestingly, in all patients, the surgical intervention produced a time-dependent effect with a U shape for AEA, PEA and OEA plasma concentrations. In contrast, 2-AG plasma concentrations increased 5 days after surgery and were reduced and stabilized 3 months later. These results suggest crosstalk between systemic and local skin endocannabinoid systems during human wound healing. AEA appears to be the most likely candidate for this link, which is deficient in patients with HT scars. Endocannabinoids are the endogenous ligands for cannabinoid receptors CB1 and CB2, which are two G-protein coupled receptors that have a widespread distribution throughout the body 1,2. The most studied endocannabinoids are the arachidonic acid derivatives N-arachidonoylethanolamine (AEA) 3 and 2-arachidonoylglycerol (2-AG) 4. Palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) are N-acylethanolamines (NAEs) that act by influencing AEA metabolism and binding to peroxisome proliferator-activated receptor alpha (PPAR-α) and to transient receptor potential cation channel subfamily V member 1 (TRPV1) 5-7. Endocannabinoids and related NAEs play an essential role in many physiological central and peripheral processes. These include emotional responses, cognition, memory, motor behaviour, immune function, feeding, energy consumption and metabolic regulation at the systemic and cellular levels 8-13. Endocannabinoids are present in human blood, and their concentrations are dynamic. Food consumption, obesity, exercise, sleep pattern, time of the day, stress, anxiety, inflammation and pain are known to modify the endocannabinoid concentrations in the circulation 14. They have also been quantified in other biological samples obtained from humans, including saliva 15 , hair 16 , semen 17 , breast milk, and amniotic fluid 18 .

show abstract

“…Indeed, one patient was weaned completely off oral opioid analgesics, and all 3 patients reported faster wound healing, less blistering, and amelioration of pain. The authors concluded that the effects might have been due to the anti-inflammatory activity of CBD, but in light of the above data, one can speculate that CBD might have beneficially modulated the keratin expression profile as well [183]. Likewise, in another small pilot study, three EB patients, who were prescribed pharmaceutical-grade sublingually administered cannabinoid-based medicine (CBM) comprising THC and CBD, reported improved pain scores, reduced pruritus and decreased overall analgesic drug intake [184].…”

Section: Translational Potential Of the Cutaneous Cannabinoid Signmentioning

confidence: 99%

Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System

et al. 2019

View full text Add to dashboard Cite

The endocannabinoid system (ECS) has lately been proven to be an important, multifaceted homeostatic regulator, which influences a wide-variety of physiological processes all over the body. Its members, the endocannabinoids (eCBs; e.g., anandamide), the eCB-responsive receptors (e.g., CB1, CB2), as well as the complex enzyme and transporter apparatus involved in the metabolism of the ligands were shown to be expressed in several tissues, including the skin. Although the best studied functions over the ECS are related to the central nervous system and to immune processes, experimental efforts over the last two decades have unambiguously confirmed that cutaneous cannabinoid (“c[ut]annabinoid”) signaling is deeply involved in the maintenance of skin homeostasis, barrier formation and regeneration, and its dysregulation was implicated to contribute to several highly prevalent diseases and disorders, e.g., atopic dermatitis, psoriasis, scleroderma, acne, hair growth and pigmentation disorders, keratin diseases, various tumors, and itch. The current review aims to give an overview of the available skin-relevant endo- and phytocannabinoid literature with a special emphasis on the putative translational potential, and to highlight promising future research directions as well as existing challenges.

show abstract

Self‐initiated use of topical cannabidiol oil for epidermolysis bullosa

Cited by 105 publications

References 14 publications

Cannabinoid Delivery Systems for Pain and Inflammation Treatment

Cannabinoid Delivery Systems for Pain and Inflammation Treatment

A new role for anandamide: defective link between the systemic and skin endocannabinoid systems in hypertrophic human wound healing

Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System

Contact Info

Product

Resources

About